Mannkind (MNKD) Current Deferred Revenue (2014 - 2026)
Mannkind (MNKD) posted quarterly Current Deferred Revenue of $11.5 million for Q1 2026, down 1.97% year-over-year from $11.8 million in Q1 2025, and down 24.83% quarter-over-quarter from $15.3 million in Q4 2025.
Mannkind (MNKD) Current Deferred Revenue (2014 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Current Deferred Revenue for 13 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 1.97% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $11.5 million (down 1.97% YoY), while the FY2025 annual figure was $15.3 million, down 75.88% from the prior year.
- Current Deferred Revenue declined to $11.5 million in Q1 2026 per MNKD's latest filing, from $15.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $78.9 million in Q4 2023 and bottomed at $1.3 million in Q1 2022.
- Historically, Current Deferred Revenue has averaged $22.2 million across 5 years, with a median of $10.1 million in 2025.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue sank 94.95% — and 2023, when it soared 5829.61%.
- Mannkind's Current Deferred Revenue stood at $63.6 million in 2022, then rose by 24.09% to $78.9 million in 2023, then dropped by 19.41% to $63.6 million in 2024, then tumbled by 75.88% to $15.3 million in 2025, then slipped by 24.83% to $11.5 million in 2026.
- Business Quant data shows MNKD's Current Deferred Revenue at $11.5 million in Q1 2026, $15.3 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.09 Mn |
| Mar 31, 2026 | 11.53 Mn |
| Dec 31, 2025 | 15.33 Mn |
| Sep 30, 2025 | 10.12 Mn |
| Jun 30, 2025 | 10.95 Mn |
| Mar 31, 2025 | 11.76 Mn |
| Dec 31, 2024 | 63.57 Mn |
| Sep 30, 2024 | 6.52 Mn |
| Jun 30, 2024 | 7.42 Mn |
| Mar 31, 2024 | 7.60 Mn |
| Dec 31, 2023 | 78.88 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 3.49 Mn |
| Mar 31, 2023 | 77.50 Mn |
| Dec 31, 2022 | 63.57 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 20.37 Mn |
| Sep 30, 2021 | 14.02 Mn |